Subgroup analysis of patients with HER2-negative metastatic breast cancer in the second-line setting from a phase 3, open-label, randomized study of eribulin mesilate versus capecitabine - Pivot, Xavier; Marmé, Frederik (Breast cancer, 2018)
Gesehen am 23.04.2020